

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 1. (Currently amended) A pharmaceutical preparation for the treatment of
2 blood coagulation disorders containing at least one pro-protein of blood coagulation selected
3 from the group consisting of factor VIII, von Willebrand factor (vWF) or factor V, and, in
4 addition, a coagulation physiologically inert receptor binding competitor selected from the group
5 consisting of receptor associated protein (RAP) RAP, a RAP mutant, a RAP analogue and the
6 combination of tissue type plasminogen activator (tPA) and aprotinin.

1 2. (Original) A preparation according to claim 1, characterized in that said
2 pro-protein is derived from a biological material selected from the group consisting of human
3 plasma, a plasma fraction and a cell culture supernatant.

1 3. (Original) A preparation according to claim 1, characterized in that it is
2 provided as a set comprising:
3 said pro-protein of blood coagulation; and
4 said receptor binding competitor.

1 4. (Original) A preparation according to claim 1, characterized in that said
2 pro-protein of blood coagulation is factor VIII and said receptor binding competitor is a mixture
3 of aprotinin and tPA.

1 5. (Original) A preparation according to claim 1, characterized in that said
2 pro-protein of blood coagulation is vWF and said binding competitor is a mixture of aprotinin
3 and tPA.

1 6. (Original) A combination preparation containing aprotinin and tPA for
2 medical use.

1 7. (Original) A method of treating a patient suffering from phenotypic
2 coagulation factor deficiency, comprising the step of administering a composition according to
3 claim 1 to said patient.

1 8. (Original) The method according to claim 7, further comprising the step of
2 selecting a patient who is vWF deficient.

1 9. (Cancelled)

1 10. (Original) The method of claim 7, wherein said receptor binding
2 competitor is a mixture of aprotinin and tPA.

1 11. (Original) The method of claim 7, wherein said pro-protein is blood
2 coagulation factor VIII.

1 12. (Cancelled)